🇺🇸 Mycophenolate Mofeti in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Myeloid Leukaemia — 1 report (10%)
  2. Alanine Aminotransferase Increased — 1 report (10%)
  3. Clostridial Infection — 1 report (10%)
  4. Disease Recurrence — 1 report (10%)
  5. Drug Clearance Decreased — 1 report (10%)
  6. Drug Interaction — 1 report (10%)
  7. General Physical Health Deterioration — 1 report (10%)
  8. Haemophilus Infection — 1 report (10%)
  9. Mycobacterial Infection — 1 report (10%)
  10. Therapy Non-Responder — 1 report (10%)

Source database →

Other Immunology approved in United States

Frequently asked questions

Is Mycophenolate Mofeti approved in United States?

Mycophenolate Mofeti does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Mycophenolate Mofeti in United States?

National Cancer Institute (NCI) is the originator. The local marketing authorisation holder may differ — check the official source linked above.